BLAINJECTIONINJECTABLEPriority Review
Approved
Nov 2022
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
TZIELD (teplizumab-mzwv) by Sanofi is cd3-directed antibody interactions [moa]. First approved in 2022.
Drug data last refreshed 12h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TZIELD (teplizumab-mzwv) is a CD3-directed monoclonal antibody administered via injection that modulates immune responses by interacting with CD3 on T cells. It is indicated for at-risk individuals to delay the onset of clinical type 1 diabetes. The drug represents an immunomodulatory approach to disease prevention in an autoimmune context.
Peak
Early-stage peak lifecycle indicates growing commercial infrastructure; modest competitive pressure (30/100) suggests market development opportunity for specialized sales and education roles.
Mechanism of Action
CD3-directed Antibody Interactions
Pharmacologic Class:
CD3-directed Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Sanofi is hiring 5 roles related to this product
Worked on TZIELD at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.